A quick question before I forget it about ,,Acalabrutinib

[michaelmac]

Good morning

I've been trying to learn about Acalabrutinib but having some problems finding much information ,,,,,,, and then deciphering it.

Anyway, my quick question ,,, is Acalabrutinib a drug that you take for a long period of time ,,,, like Imatinib ...... my understanding with Imatinib is most people take it until it stops working.,,,

This is just a general question not about people one studies or other things.

Thanks for your help

have a great day

Michael

[Hidden]

have you googled Calquence

[michaelmac in reply to Hidden]

Hi

thanks for your reply ,,,, I would be the first one to admit that I don't really write very well or always get my meaning/question out there.

In this case

""Anyway, my quick question ,,, is Acalabrutinib a drug that you take for a long period of time ,,,, like Imatinib ...... my understanding with Imatinib is most people take it until it stops working.,,,""

So, at this time I'm just trying to get information about,,,,,Acalabrutinib

sorry I didn't make that clear the first time around

Hope everyone is having a good day

Michael

[bkoffman CLL CURE Hero]

Right now BTKi such as Acalabrutinib are taken until progression or they are no longer tolerated. That may be changing with new fixed duration combinations. Brian CLLSociety.org

[michaelmac in reply to bkoffman]

Thanks

m

[Jm954 Administrator]

This is from an on line publication on 24/10/19:

Potential for Fixed-Duration BTK Inhibitor Therapy

"With the impressive efficacy of the currently approved BTK inhibitors, as well as those in late-stage development, the next question becomes: Can we develop treatment regimens including BTK inhibitors that may allow for fixed-duration approaches? The idea of delivering time-limited therapy to patients with novel agents is quite appealing. The current approach being explored is to use these highly potent BTK inhibitors to treat patients for a specific, defined period of time and achieve undetectable minimal residual disease (uMRD). Then, once uMRD is achieved, therapy can likely be stopped and allow the patient can remain off therapy for an extended time.

At relapse, which is common with indolent lymphomas and certainly with CLL, BTK inhibitor–based therapy might be reinitiated to provide additional benefit to patients. This idea of fixed-duration treatment may extend the use of this class of agents and provide a significant clinical benefit for patients. Current studies investigating time limited therapy are on-going."

There's more information on the website about the new generation BTK inhibitors here but you need to register: clinicaloptions.com/oncolog...

Hope this is useful.

Jackie

[michaelmac]

Thanks ,,perfect

[bhayes84]

Ivotedfornixon mentioned Calquence because that's the brand name of the drug Acalabrutinib (which is a 2nd generation BTK inhibitor whereas Ibrutinib is a 1st generation). Many (most?) people on Acala started out on Ibrutinib but had side effects such as afib or skin problems.